ERBB2 and non-small cell lung carcinoma: In the subsequent phase II basket trial, 18 patients with advanced NSCLC and HER2 genomic alterations were treated with T-DM1 3.6 mg/kg intravenously every 3 weeks, resulting in an ORR of 44% (95% CI, 22% to 69%) and an mPFS of 5 months (95% CI, 3 to 9 months).